SPRB · NASDAQ · Biotechnology

Spruce Biosciences (SPRB)

Develops an enzyme therapy for Sanfilippo syndrome and a preclinical CAH antibody.

$59.00
Pre-market−0.68 (−1.14%)
At close$59.68(+7.34%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
estimated · in 67 days
EPS estimate
−$5.86
Revenue estimate
$50.0M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$24.06−$3.50−$14.58−$9.58−$8.94−$6.68−$6.68Pending
Estimate−$18.80−$18.05−$15.56−$12.87−$7.32−$5.79−$5.79−$5.86
Surprise−28.0%+80.6%+6.3%+25.6%−22.1%−15.4%−15.4%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate$250.0K$500.0K$50.0M
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$5.86
Aug 2026−$5.79−$6.68−15.4%
Aug 2026−$5.79−$6.68−15.4%
May 2026−$7.32−$8.94−22.1%
Mar 2026−$12.87−$9.58+25.6%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Apr 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Oct 2020
Mar 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$5.86$50.0M
Aug 13, 2026−$5.79−$6.68−15.4%+5.7%
Aug 12, 2026−$5.79−$6.68−15.4%+1.4%
May 13, 2026−$7.32−$8.94−22.1%+2.5%
Mar 9, 2026−$12.87−$9.58+25.6%$500.0K+1.1%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 10, 2025
Aug 14, 2025
May 6, 2025
Apr 2, 2025
Nov 11, 2024
Aug 12, 2024
May 13, 2024
Mar 13, 2024
Nov 13, 2023
Aug 14, 2023
May 15, 2023
Mar 16, 2023
Nov 10, 2022
Aug 10, 2022
May 11, 2022
Mar 14, 2022
Nov 15, 2021
Aug 10, 2021
May 12, 2021
Mar 22, 2021
Nov 18, 2020
Oct 9, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019